Gepotidacin Brand names: Blujepa

What is gepotidacin used for?

From the label: indications and usage

BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of the following infections caused by susceptible microorganisms:

Uncomplicated urinary tract infections (uUTI) in female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg). ( 1.1 )

Uncomplicated urogenital gonorrhea in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms who have limited or no alternative treatment options. Approval of this indication is based on limited clinical safety data for this indication. […]

Conditions named in the indications of gepotidacin's FDA labels, with every medicine labeled for each:

• Urinary tract infections

FDA pharmacologic class: Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor.

What does the patient leaflet for gepotidacin say first?

The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.

From the patient leaflet: What is the most important information I should know about BLUJEPA?

BLUJEPA, an antibiotic, can cause serious side effects, including: • changes in electrical activity of your heart called QTc prolongation. BLUJEPA can cause QTc prolongation (also called prolonged QTc interval) that can lead to serious heart rhythm problems, including Torsade de Pointes. There may be changes in your heartbeat (a fast or irregular heartbeat). Before starting BLUJEPA, tell your healthcare provider if you: o or anyone in your family has ever had a heart rhythm problem (problem with heart rate or heartbeat) or QTc prolongation. o are taking any medicines to treat heart rhythm problems. Using these medicines with BLUJEPA may cause serious side effects. If you are not sure, ask your healthcare provider. o are taking medicines called moderate or strong CYP3A4 inhibitors. Using these medicines with BLUJEPA may cause serious side effects. If you are not sure, ask your healthcare provider. Tell your healthcare provider right away if you have any of the following symptoms: ○fast, pounding, or uneven heartbeat ○feeling dizzy ○you lose consciousness (pass out) ○feeling lightheaded ○feeling faint • an increase of a certain chemical in your nervous system (cholinergic effects). BLUJEPA can cause an increase of a certain chemical in your nervous system, which may cause the following symptoms: ○diarrhea ○vomiting ○fainting ○trouble saying words clearly ○muscle spasms ○nausea ○more saliva in the mouth ○more sweating ○stomach pain Call your healthcare provider right away if you have trouble saying words clearly, have shortness of breath, or if you faint. These symptoms may be cholinergic effects of BLUJEPA. The increased chemical in your nervous system can also be connected to other symptoms. […]

From the patient leaflet: How should I store BLUJEPA?

Store BLUJEPA tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep BLUJEPA and all medicines out of the reach of children.

Is there a generic for gepotidacin (Blujepa)?

No generic gepotidacin is approved (Drugs@FDA, October 8, 2026).

The Orange Book lists 4 patents for Blujepa tablets: the compound patent runs to December 13, 2042. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

What do pharmacies pay for gepotidacin (Blujepa)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $91.40 per Blujepa 750 mg tablet. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

What does the gepotidacin label say about other medicines?

The gepotidacin label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Check gepotidacin against other medicines

What do FAERS reports show for gepotidacin?

The FDA Adverse Event Reporting System holds 22 reports that list gepotidacin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 0 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

• Diarrhoea (named in the label)6
• Off Label Use (a use or a product term, not a reaction)3
• Abdominal Pain (named in the label)2
• Dizziness (named in the label)2
• Dysarthria (named in the label)2
• Nausea (named in the label)2
• Abdominal Pain Upper (named in the label)1
• Asthenia1

What else is labeled for the same conditions as gepotidacin?

9 other medicines are given the same way (oral) and in the same FDA class as gepotidacin or labeled mainly for the same use (urinary tract infections), the same class first. Urinary tract infections lists all 39 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Every medicine labeled for the same conditions as gepotidacin

What next?

Alternatives to gepotidacin

9 medicines for the same use

Gepotidacin side effects

the label's list beside FAERS reports

Check an interaction

what two or more labels say about each other